Alpha Hormones gives a capsule-focused reader an unusually direct starting point: its hormone-care page names oral micronized progesterone among FDA-approved treatment options. That is more specific than a general menopause advertisement. It still does not identify which product, if any, would appear on an individual prescription.
We reviewed Alpha Hormones’ treatment, pricing and subscription information on September 29, 2026. This assessment separates the published treatment category from a dispensing label, and separates a recurring payment from the work of obtaining a refill. Access is described for particular states rather than assumed to be nationwide.
In this article
The oral option is explicit, but the manufacturer is not
The hormone-treatment page names FDA-approved oral micronized progesterone alongside other hormone options. It also discusses compounded treatments in its broader program. This confirms a published oral treatment category; it does not establish the manufacturer, capsule ingredients, pharmacy or prescription that a particular reader would receive.
The medicine-role guide starts with the purpose of a proposed medicine, rather than treating every menopause symptom as a reason for the same prescription. Alpha’s individualized-care wording leaves that clinical decision with the treating professional. The review therefore distinguishes a verified listed option from a verified supply of a named product, including Prometrium.
Approved and compounded preparations need separate explanations
The two categories on the treatment page should remain distinct throughout a consultation. The FDA states that compounded drugs are not FDA approved and that it does not verify their safety, effectiveness or quality before marketing. A reference to an approved oral option cannot confer that status on a different compounded preparation.
If the proposed treatment differs from an approved product’s labeled use, that raises another question. FDA’s off-label explanation concerns use of an approved drug for an unapproved purpose; it does not make a compounded medicine approved. Defy’s review provides a useful comparison with a broader route menu. The relevant distinction is the actual proposal, not which service uses more reassuring terminology.
The ingredient answer requires more than an active name
The public Alpha description does not supply a complete ingredient record for a specific capsule. The excipient guide explains why that missing information matters separately from the amount of active medicine. A person’s ingredient concern cannot be resolved by the word micronized or by an assurance that a plan is tailored.
The FDA label for Prometrium identifies peanut oil and gelatin and specifically excludes use by patients allergic to peanuts. That label is an example of exact product information, not proof that Alpha prescribes that brand or that all alternatives share its ingredients. The prescriber or dispensing pharmacist should identify the applicable record for whatever preparation is actually proposed.
A starting subscription price is not a standalone capsule price
Alpha’s pricing page advertises women’s hormone therapy starting at $349 per month or $3,490 per year, with a one-time $200 setup fee. It describes consultations, tailored laboratory work, medicines, supplies and free shipping within the subscription. The subscription policy specifies one fifteen-minute video or in-person consultation per month after the first month. It also identifies additional products or services that can carry separate costs. The starting figure is therefore a program description, not a confirmed oral-progesterone-only quote.
The relevant comparison is the written arrangement offered after assessment, with the commitment and exclusions intact. BodyLogicMD’s review examines a membership that prices tests and treatments separately. Those offers cannot be compared as though both headline figures purchased the same capsule and the same professional follow-up.
Recurring billing and medicine refills follow different rules
The subscription policy states that recurring billing does not automatically generate refills: patients need to request them. That is an operational point worth understanding before enrollment. It does not establish a personal refill interval or how much medicine a particular prescription would supply.
The same policy calls for written cancellation thirty days before the next billing date, says payments are not prorated and excludes returns of prescription medicines. These are the provider’s stated purchase conditions, not a general legal conclusion about every situation. The follow-up guide helps separate a billing cancellation request from a clinical question about continuing care. Neither should be assumed to resolve the other without explicit confirmation.
State access and insurance still need individual confirmation
The pricing information describes telemedicine access for residents of California, Texas and Florida, with an in-person location in Pasadena. It also describes accepted insurance categories and exclusions. Those statements establish the advertised service area and administrative approach; they do not verify an individual appointment, benefit, medicine copayment or covered laboratory service.
Someone outside those states should not infer eligibility from the availability of the website. Someone within them still needs the selected appointment and financial arrangement confirmed. A consultation price, subscription price and insurer payment are different records. Preserving those distinctions is particularly useful when an existing clinician or outside pharmacy will remain involved in part of the care.
The practical question is who explains and follows the prescription
The Alpha service page presents hormone care as individualized. A useful explanation would connect the chosen medicine’s purpose with its precise identity, expected assessment and contact route for concerns. It would also name who handles prescription questions when the request concerns a side effect rather than a renewal or payment.
For the exact Prometrium product, the FDA label warns about dizziness and drowsiness, including caution around driving and machinery. The drowsiness guide offers questions without turning that warning into a personal schedule. Alpha’s published oral option makes a focused conversation possible; it does not replace that conversation with a universal capsule recommendation or a guaranteed outcome.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Alpha Hormones: Bioidentical hormone replacement therapyProvider treatment menu naming FDA-approved oral micronized progesterone and separately compounded options; no exact prescribed product confirmed · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- FDA: Understanding Unapproved Use of Approved Drugs, Off LabelFederal explanation of off-label use of an approved drug; distinct from approval status of a compounded preparation · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- Alpha Hormones: PricingProvider program starting prices, setup fee, access and insurance descriptions; individual selection and benefits remain unverified · Checked 2026-09-29
- Alpha Hormones: Subscription cancellation policyProvider recurring billing, refill-request and cancellation/return conditions; attributed purchase policy, not generalized legal advice · Checked 2026-09-29